Recognition of Impaired Atomoxetine Metabolism Because of Low CYP2D6 ActivityTER LAAK, Maureen A; TEMMINK, Alphons H; KOEKEN, Ankie et al.Pediatric neurology. 2010, Vol 43, Num 3, pp 159-162, issn 0887-8994, 4 p.Article

Atomoxetine treatment of attention-deficit/hyperactivity disorderEILAND, Lea S; GUEST, Abby L.The Annals of pharmacotherapy. 2004, Vol 38, Num 1, pp 86-90, issn 1060-0280, 5 p.Article

Atomoxetine Tolerability in Pediatric and Adult Patients Receiving Different Dosing StrategiesWIETECHA, Linda A; RUFF, Dustin D; ALLEN, Albert J et al.The Journal of clinical psychiatry. 2013, Vol 74, Num 12, pp 1217-1223, issn 0160-6689, 7 p.Article

Atomoxetine and Cerebrovascular Outcomes in AdultsHOLICK, Crystal N; TURNBULL, Bruce R; JONES, Meghan E et al.Journal of clinical psychopharmacology. 2009, Vol 29, Num 5, pp 453-460, issn 0271-0749, 8 p.Article

Augmentation with open-label atomoxetine for partial or nonresponse to antidepressantsCARPENTER, Linda L; MILOSAVLJEVIC, Nada; SCHECTER, Jordan M et al.The Journal of clinical psychiatry. 2005, Vol 66, Num 10, pp 1234-1238, issn 0160-6689, 5 p.Article

Atomoxetine in the Treatment of Adults with Subthreshold and/or Late Onset Attention-Deficit Hyperactivity Disorder-Not Otherwise Specified (ADHD-NOS): A Prospective Open-Label 6-Week StudySURMAN, Craig; HAMMERNESS, Paul; PETTY, Carter et al.CNS neuroscience & therapeutics (Print). 2010, Vol 16, Num 1, pp 6-12, issn 1755-5930, 7 p.Article

Efficacy of atomoxetine in adults with attention deficit hyperactivity disorder: An integrated analysis of the complete database of multicenter placebo-controlled trialsASHERSON, Philip; BUSHE, Chris; SAYLOR, Keith et al.Journal of psychopharmacology (Oxford). 2014, Vol 28, Num 9, pp 837-846, issn 0269-8811, 10 p.Article

Evaluation of a head-to-head study of lisdexamfetamine dimesylate and atomoxetineBANASCHEWSKI, Tobias; ROTHERMEL, Boris; POUSTKA, Luise et al.Expert opinion on pharmacotherapy. 2014, Vol 15, Num 13, pp 1961-1965, issn 1465-6566, 5 p.Article

Prefrontal grey and white matter neurometabolite changes after atomoxetine and methylphenidate in children with attention deficit/hyperactivity disorder: A ¹H magnetic resonance spectroscopy studyHUSAROVA, Veronika; BITTSANSKY, Michal; ONDREJKA, Igor et al.Psychiatry research. Neuroimaging. 2014, Vol 222, Num 1-2, pp 75-83, issn 0925-4927, 9 p.Article

Atomoxetine for attention deficit hyperactivity disorder in the adulthood: a meta-analysis and meta-regressionCUNILL, Ruth; CASTELLS, Xavier; TOBIAS, Aurelio et al.Pharmacoepidemiology and drug safety. 2013, Vol 22, Num 9, pp 961-969, issn 1053-8569, 9 p.Article

Long-Term Quality-of-Life and Functioning Comparison of Atomoxetine Versus Other Standard Treatment in Pediatric Attention-Deficit/Hyperactivity DisorderFUENTES, Joaquin; DANCKAERTS, Marina; CARDO, Esther et al.Journal of clinical psychopharmacology. 2013, Vol 33, Num 6, pp 766-774, issn 0271-0749, 9 p.Article

Atomoxetine increases fronto-parietal functional MRI activation in attention-deficit/hyperactivity disorder: A pilot studyBUSH, George; HOLMES, Jennifer; SHIN, Lisa M et al.Psychiatry research. Neuroimaging. 2013, Vol 211, Num 1, pp 88-91, issn 0925-4927, 4 p.Article

Driving performance in adults with ADHD: Results from a randomized, waiting list controlled trial with atomoxetineSOBANSKI, E; SABLJIC, D; ALM, B et al.European psychiatry. 2013, Vol 28, Num 6, pp 379-385, issn 0924-9338, 7 p.Article

Synergistic Effect of Norepinephrine Transporter Blockade and α-2 Antagonism on Blood Pressure in Autonomic FailureOKAMOTO, Luis E; SHIBAO, Cyndya; GAMBOA, Alfredo et al.Hypertension (Dallas, Tex. 1979). 2012, Vol 59, Num 3, pp 650-656, issn 0194-911X, 7 p.Article

Blockade of noradrenaline re-uptake sites improves accuracy and impulse control in rats performing a five-choice serial reaction time tasksROBINSON, Emma S. J.Psychopharmacologia. 2012, Vol 219, Num 2, pp 303-312, issn 0033-3158, 10 p.Article

VARIABLE PRENATAL STRESS RESULTS IN IMPAIRMENTS OF SUSTAINED ATTENTION AND INHIBITORY RESPONSE CONTROL IN A 5-CHOICE SERIAL REACTION TIME TASK IN RATSWILSON, C. A; SCHADE, R; TERRY, A. V et al.Neuroscience. 2012, Vol 218, pp 126-137, issn 0306-4522, 12 p.Article

Genetic polymorphisms in the treatment of depression: Speculations from an augmentation study using atomoxetineREIMHERR, Frederick; AMSTERDAM, Jay; FELDMAN, Peter et al.Psychiatry research (Print). 2010, Vol 175, Num 1-2, pp 67-73, issn 0165-1781, 7 p.Article

Methylphenidate and Atomoxetine Enhance Prefrontal Function Through α₂-Adrenergic and Dopamine D₁ ReceptorsGAMO, Nao J; MIN WANG; ARNSTEN, Amy F. T et al.Journal of the American Academy of Child and Adolescent Psychiatry. 2010, Vol 49, Num 10, pp 1011-1023, issn 0890-8567, 13 p.Article

Atomoxetine for the Treatment of Executive Dysfunction in Parkinson's Disease : A Pilot Open-Label StudyMARSH, Laura; BIGLAN, Kevin; GERSTENHABER, Melissa et al.Movement disorders. 2009, Vol 24, Num 2, pp 277-282, issn 0885-3185, 6 p.Article

A Haplotype of the Norepinephrine Transporter (Net) Gene Slc6a2 is Associated with Clinical Response to Atomoxetine in Attention-Deficit Hyperactivity Disorder (ADHD)RAMOZ, Nicolas; BOI, Claudette; DOWNING, Anncatherine M et al.Neuropsychopharmacology (New York, NY). 2009, Vol 34, Num 9, pp 2135-2142, issn 0893-133X, 8 p.Article

Once-Daily Atomoxetine for Adult Attention-Deficit/Hyperactivity Disorder : A 6-Month, Double-Blind TrialADLER, Lenard A; SPENCER, Thomas; BROWN, Thomas E et al.Journal of clinical psychopharmacology. 2009, Vol 29, Num 1, pp 44-50, issn 0271-0749, 7 p.Article

Risperidone-induced sexual dysfunction in a prepubertal child -a case reportWADOO, O; CHALHOUB, N.Journal of psychopharmacology (Oxford). 2009, Vol 23, Num 6, pp 727-728, issn 0269-8811, 2 p.Article

Mortality Associated with Attention- Deficit Hyperactivity Disorder (ADHD) Drug Treatment: A Retrospective Cohort Study of Children, Adolescents and Young Adults Using the General Practice Research DatabaseMCCARTHY, Suzanne; CRANSWICK, Noel; POTTS, Laura et al.Drug safety. 2009, Vol 32, Num 11, pp 1089-1096, issn 0114-5916, 8 p.Article

A quality by design approach to impurity method development for atomoxetine hydrochloride (LY139603)GAVIN, Peter F; OLSEN, Bernard A.Journal of pharmaceutical and biomedical analysis. 2008, Vol 46, Num 3, pp 431-441, issn 0731-7085, 11 p.Article

Pharmacological manipulations of interval timing using the peak procedure in male C3H miceBALCI, Fuat; LUDVIG, Elliot A; GIBSON, Jacqueline M et al.Psychopharmacologia. 2008, Vol 201, Num 1, pp 67-80, issn 0033-3158, 14 p.Article